EHBP1: A ProteinLinked To Many Diseases and A Potential Drug Target

Target Name: EHBP1

NCBI ID: G23301

EHBP1

EHBP1: A ProteinLinked To Many Diseases and A Potential Drug Target

EHBP1 (EHBP1 variant 3) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is embedded in its name, which stands for EHBP1 gene-encoded protein 1.

The importance of EHBP1 is that it has been linked to a number of diseases, including heart disease, diabetes, and neurodegenerative disorders. Additionally, it is a potential drug target for several therapies that are currently being developed or have already been approved for use.

One of the key challenges in studying EHBP1 is its complex structure. While it is a protein that is expressed in many different tissues of the body, its exact location and function in each of these tissues is not well understood. This lack of understanding has made it difficult to develop effective treatments for EHBP1-related diseases.

In addition to its challenges in structure, EHBP1 is also known for its role in several signaling pathways that are important for cellular growth and development. It has been shown to play a role in the development and progression of cancer, as well as in the regulation of cellular signaling pathways that are important for things like cell division and survival.

Given the complex structure and role of EHBP1 in cellular signaling pathways, it is not surprising that it is a potential drug target. Many researchers and pharmaceutical companies are currently working on developing drugs that can specifically target EHBP1 and modulate its activity.

One of the leading candidates for EHBP1-related drugs is a compound called BAY 94-9343. This compound is a small molecule that can inhibit the activity of EHBP1 and has been shown to be effective in animal models of several EHBP1-related diseases, including heart disease and neurodegenerative disorders.

Another potential drug for EHBP1 is a monoclonal antibody that is designed to target EHBP1 specifically. This antibody has been shown to be effective in animal models of several EHBP1-related diseases, including heart disease and neurodegenerative disorders.

While the development of drugs that specifically target EHBP1 is an important step in the treatment of EHBP1-related diseases, it is also important to consider the potential unintended consequences of these treatments. For example, the use of some drugs that target EHBP1 have been shown to cause unintended side effects in other tissues of the body. This is an important consideration when developing and implementing new treatments for EHBP1-related diseases.

Overall, EHBP1 is a protein that has been linked to a number of diseases and has the potential to be a drug target for several therapies. While the development of effective treatments for EHBP1-related diseases is an important step, it is also important to carefully consider the potential unintended consequences of these treatments.

Protein Name: EH Domain Binding Protein 1

Functions: May play a role in actin reorganization. Links clathrin-mediated endocytosis to the actin cytoskeleton. May act as Rab effector protein and play a role in vesicle trafficking (PubMed:14676205, PubMed:27552051). Required for perinuclear sorting and insulin-regulated recycling of SLC2A4/GLUT4 in adipocytes (By similarity)

The "EHBP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EHBP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets